I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.¶
Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., & Esserman, L. (2009). I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical Pharmacology & Therapeutics, 86(1), 97-100.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Bayesian Updating
- The I-SPY 2 trial for neoadjuvant breast cancer treatment, initiated in 2010 by UCSF investigators in collaboration with the FDA and industry partners, is a landmark application of Bayesian adaptive design in oncology
This sourceSUPPORTS marker 011 (re-sourced from jeffreys-1961, which is about objective priors and does not concern I-SPY 2).
- The I-SPY 2 trial for neoadjuvant breast cancer treatment, initiated in 2010 by UCSF investigators in collaboration with the FDA and industry partners, is a landmark application of Bayesian adaptive design in oncology
Verification¶
This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.
Registry ID ref:08ca7097e2e5 · see in the full table